Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Modelled patients were assumed to receive once-weekly semaglutide or dulaglutide for 3 years, in line with previously published analyses of GLP-1 receptor agonists and data from general practice in Europe, which reported a mean duration of treatment with GLP-1 receptor agonists of 29.35 months (rounded to 3 years, as treatment switching in the IQVIA CORE Diabetes Model can only occur at the end of an annual cycle) [14, 29,30,31]
Patients can apply HSA or FSA funds toward PlexusDx compounded medications, effectively reducing net out-of-pocket costs for those with eligible healthcare savings accounts
The CAS number for BPC-157 is 137525-51-0, which uniquely identifies the compound for research and regulatory reference
August 8, 2025
Please reach out to one of our doctors at Mobi Doctor for more information.
US$ 29.87
US$ 27.64
US$ 21.98
US$ 22.60
US$ 29.86
